Tag: DOACs
-
Stopping DOACs After Successful AF Ablation: OCEAN Trial Feasible in Low-Risk Patients
Overview: Rethinking Anticoagulation After AF Ablation New data from the OCEAN trial suggest that stopping direct oral anticoagulants (DOACs) after a successful atrial fibrillation (AF) ablation may be feasible for low-risk patients. This challenges the long-standing practice of continuing anticoagulation based solely on prior AF history and CHADS2‑VASc scoring, and invites clinicians to re-evaluate individual…
-
Stopping DOACs After Successful AF Ablation: Feasible in Low-Risk Patients? Insights from OCEAN Trial
New Evidence Questions Long-Term Anticoagulation After AF Ablation For patients with atrial fibrillation (AF) who undergo successful ablation, clinicians often face the question: should a patient continue taking a direct oral anticoagulant (DOAC) or switch to an antiplatelet strategy like aspirin? The OCEAN trial, presented in New Orleans, Louisiana, provides new data suggesting that, among…
-
Common Pitfalls of Polypharmacy in Heart Failure and Mortality Risk
Understanding the Mortality Link: Polypharmacy in Heart Failure Polypharmacy, defined as the use of multiple medications, is common among patients with heart failure. A 2022 study found that polypharmacy is significantly associated with higher mortality, with a relative risk of 1.31 (95% CI 1.07–1.61). Notably, this risk appears most pronounced when multiple non-guideline-directed drugs are…